I'm long GHDX but I know that molecular diagnostics / genetic testing is getting to be an increasingly crowded space. Do you have any concerns about competition chipping away at revenues? I'm long, but wonder about erosion of revenue by co's w/ cheaper tests that insurance co's might have more favorable reimbursement payout to. I know GHDX is a leader in this field, but payers might be inclined to give a nod to a lower cost test when they prove similar efficacy to OncoDx. That's my only concern here. What's your take? Thanks.
I think Terry has more knowledge than me on GHDX, and I agree with him. Their R&D is phenomenal, creating enormous value. They are rock solid in their endeavor to have a real impact on patients who suffer from these horrible diseases, providing priceless value to those facing life-altering treatment options. It's worth $100 if it's worth a dime. I do believe it will double on prostate projections/numbers this year as well as their continued R&D surprises, and of course, the backing of the Bakers on the BOD. They are good guys for building a company of such noble value. That alone deserves my nickel.
I aint Frank) , but I am surely the largest and most owned SH on this board. As Rose posted it will be awhile for steep ramp up in prostate revenues, but those "chipping away" are really not the competition. GHDX has spent so much on R&D unlike anything I have ever seen in bio.The validation and the results will follow the NICE stuff, and yes it will all be owned by someone else ; - ). Building this company has been what Genomic Health is about - not profits or SP. I've added more over the holidays
Think you probably already know. Terry is Frank and Rose. This terry id guy get off on multi ids to back up and build up his terry ids. This guys needs help. He got slammed on AMLN at above and seemed to have loss it ever since then.
heads up-one of your posters terry visited our board with comments about the gigigle guy and started his on gigigle id on our board. He could be gigigle on both boards. al
I have to agree. After looking over the bio's of the B.O.D. on GHDX's website, I'd have to say it's an impressive group. Just a matter of being patient until the OncoDx-prostate numbers start showing good Qtr/over/Qtr growth. The only question is whether Medicare's reimbursement rates will kick in the full amount.